Altimmune (NASDAQ:ALT) Issues Earnings Results, Beats Expectations By $0.03 EPS

Altimmune (NASDAQ:ALT) issued its quarterly earnings data on Tuesday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03, Zacks reports. The firm had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 52.60%. During the same period in the previous year, the firm earned ($0.39) EPS.

Altimmune Stock Performance

Shares of ALT stock traded down $0.66 on Thursday, reaching $8.86. 2,043,801 shares of the company were exchanged, compared to its average volume of 3,850,871. The company has a market cap of $629.68 million, a price-to-earnings ratio of -5.73 and a beta of 0.09. Altimmune has a 1 year low of $2.34 and a 1 year high of $14.84. The business has a 50-day moving average price of $6.95 and a 200 day moving average price of $6.89.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Thursday. UBS Group assumed coverage on shares of Altimmune in a research report on Tuesday. They set a “buy” rating and a $26.00 target price on the stock. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Finally, B. Riley reissued a “buy” rating and set a $20.00 price objective on shares of Altimmune in a report on Monday, August 12th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Altimmune presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Insider Buying and Selling at Altimmune

In other news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the sale, the director now owns 41,958 shares of the company’s stock, valued at $289,510.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.10% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.